科学 · 诺贝尔化学奖
卡根和Soai因让分子手性发挥作用而获诺贝尔化学奖
他们的发现有助于化学家偏向预期的镜像分子,也展示了微小的不平衡如何不断扩大。这对药物很重要,但不能证明生命如何获得其手性。
原语言视频
文字实录 · 正在加载
译自英文原文。
新闻追踪第 1 天
1 篇报道23 家媒体43 个来源2 个视频
对于服用药物的人来说,分子的形状可能与其化学式同样重要。两个互为镜像的版本与生物体的相互作用可能不同。因此,制备出预期的版本,不只是要获得正确的原料,还要把它们排列成正确的三维形态。今年诺贝尔化学奖所表彰的发现,为化学家提供了偏向某一版本的方法;在适当的反应中,还能将几乎难以察觉的偏好放大到压倒性程度。1 12
2026年诺贝尔化学奖授予亨利·B·卡根和Kenso Soai。瑞典皇家科学院于10月7日星期三在斯德哥尔摩宣布了这一消息。官方颁奖词表彰他们“发现了不对称有机合成中的非线性效应和自催化现象”。公告列明,卡根任职于法国巴黎第十一大学,Soai任职于日本东京理科大学。4 5
据NPR报道,诺贝尔化学奖奖金总额为1,200万瑞典克朗,约合$1.2 million。NewKerala报道称,获奖者将平分奖金;现有官方公告摘录未能证实这一分配方式。1,200万克朗是奖金总额,并非每位科学家各获这么多。1 15
实际重要性与更深层的科学谜题,都汇聚在同一个问题上:化学如何形成强烈的单向性?
为什么镜像很重要
举起双手看看。它们互为镜像,但无论怎样旋转其中一只,都无法让它在各方面与另一只完全重合。某些分子也具有这种性质。它们互为镜像的形式称为对映体;不对称有机合成会偏向其中一种,而不是让两种形式等量生成。同手性描述的是一种手性的选择或占主导地位。单凭化学式无法体现这种区别。12 13
正如BBC科学记者帕拉布·戈什所解释的,卡根在20世纪80年代的研究表明,某些反应能够放大对某一种手性的偏好。催化剂中的不平衡与所得产物中的不平衡不一定按简单比例增加。在适当的体系中,产物可能表现出更强的偏好。这就是非线性效应,并不意味着每一种不对称反应都会放大手性。2
Soai的研究提出了一种自我强化机制。在不对称自催化中,手性反应产物本身有助于催化生成更多同一种产物。已有的偏好可以通过反馈推动进一步生成并不断增强。反应不只是保留初始的不平衡,还能将其强化。2 26
已发表的发现记录包括Soai、Takanori Shibata、Hiroshi Morioka及其同事于1995年发表在《自然》上的论文《不对称自催化与手性分子对映体过量的放大》。这能确认该论文的主题与发表年份,但不能据此认定所有后续放大结果都出自这篇首发论文。43
从几乎平衡到压倒性偏向一方
一份日期为2014年1月22日的后续研究说明给出了一个引人注目的例子。在一个涉及2-炔基嘧啶基烷醇的体系中,约0.00005%的初始对映体过量被放大到同一种化合物中超过99.5%的对映体过量。28
关键事实
关键术语是对映体过量:它衡量两种互为镜像的形式之间的不平衡。这不是化学产率,也不意味着制造过程中使用的全部物料中有99.5%变成了预期产品。用报告的最终阈值除以近似起始值,得出的这一指标增幅超过约199万倍;这并不是一个另行精确测定的实验放大倍数。28
所述化学反应以嘧啶基烷醇为不对称自催化剂,使二异丙基锌加成到嘧啶-5-甲醛上。这个极小的起始不平衡属于特定的2-炔基嘧啶基烷醇体系,并非某种未指明的通用反应。2002年7月的一份报告还描述了涉及嘧啶甲醛、喹啉甲醛和吡啶甲醛的反应中的放大现象。28 22
现有描述没有指出这一极端案例最初实验的日期、反应循环次数或完整步骤。这些缺失限制了对实验的详细还原,但并未抹去报告的结果;不过,它们意味着不能把这一结果当作在任何条件下都适用的配方。
改进反应设计,而非笼统宣称安全
据NPR报道,诺贝尔委员会称,这些发现对设计药品制造反应的化学家具有决定性意义。这是一项重大成就,但不应被夸大成别的东西:该奖项并未宣布一种新疗法,没有证明药价会降低,也不保证每一种生产工艺都更安全。1
谈及常见的药物例子时也需要谨慎。DW在10月7日的节目中将沙利度胺相关讨论放在20世纪90年代中期,并引用了估计有20,000名婴儿死亡的数字。这里核查的研究说明将这场灾难定位在20世纪50年代末;死亡人数估计未经核实。有关沙利度胺光学异构体差异的报告,并不能证明“一个无害、另一个有害”这种简单说法,也不能证明选择单一对映体就能消除危害。3 33 36
DW关于布洛芬两种镜像形式中只有一种具有药效的解释,同样需要谨慎。现有研究摘录并未证实这种“只有一种有药效”的说法,也没有确定不同形式之间代谢转化的程度。诺贝尔奖的意义并不依赖于把一种复杂药物简化成整齐的“好分子/坏分子”例证。3 34 39
一种机制不等于生命的历史
据NPR报道,委员会主席海纳·林克称,这些发现为“同手性如何自发产生这一百年谜题”提供了解决方案。他的评价涉及一种能形成强烈分子偏好的途径,不应被延伸为生物手性的实际历史起源已获证明。1
在实验室中证明放大效应,与证明这一特定反应发生在生命出现之前,或解释生物为何选择某一种手性,并不是一回事。Soai体系是研究各种可能性的工具,并非对生命起源过程的实证重现。28
划清这一界限并不会削弱这项成就。卡根和Soai表明,化学不必只能接受反应起始时的比例。在适当的体系中,反应可以偏向预期的镜像产物,并放大极微小的偏好。对于药物反应设计而言,这是有用的控制手段;对于理解生命的手性而言,这是一种得到证实的可能性,而非最终的历史答案。
来源与支持性研究
NPR:亨利·B·卡根和Kenso Soai获得诺贝尔化学奖。1
BBC新闻:10月7日《全球新闻播客》化学专题。2
DW新闻:为什么这项诺贝尔化学奖对现代医学意义重大。3
瑞典皇家科学院:2026年诺贝尔化学奖。4
NobelPrize.org:英文新闻稿。5
瑞典皇家科学院:科学背景资料。6
NobelPrize.org:新闻稿PDF。7
瑞典皇家科学院:他们解开了化学不对称之谜。8
瑞典皇家科学院:新闻稿PDF。9
NobelPrize.org:瑞典语新闻稿。10
《科学》:诺贝尔奖表彰解开化学不对称之谜的研究人员。11
NobelPrize.org:通俗介绍。12
瑞典皇家科学院:通俗科学背景资料。13
英国皇家化学学会:亨利·卡根和Kenso Soai获2026年诺贝尔化学奖。14
NewKerala:2026年诺贝尔化学奖:卡根、Soai因镜像分子研究获奖。15
NobelPrize.org:科学背景资料PDF。16
《自然·通讯》:Soai对吡啶基和嘧啶基底物的不对称自催化反应的机理分析与动力学研究。17
NobelPrize.org:通俗科学背景资料PDF。18
《化学世界》:自催化和非线性效应解读。19
Heise:不对称的微小提示如何产生同手性。20
嘧啶基烷醇的不对称自催化及其在同手性起源研究中的应用。21
不对称自催化及其在手性判别中的应用。22
东京理科大学托管的Soai研究工作文档。23
出版记录:不对称自催化与手性分子对映体过量的放大。24
《不对称自催化的发现与发展》,出版方记录。25
《不对称自催化的发现与发展》,研究说明。26
不对称自催化与生物分子的同手性。27
利用不对称自催化研究同手性的起源。28
东京理科大学托管的《不对称自催化与生物分子同手性的起源》。29
不对称自催化与有机化合物手性均一性的起源。30
Heise:因发现非线性效应而获诺贝尔化学奖。31
《波士顿环球报》:诺贝尔化学奖授予亨利·卡根和Kenso Soai。32
《科学报告》:通过对映体自身歧化理解生物过程中的沙利度胺手性。33
芳基丙酸类药物的药效学与药代动力学,特别涉及S(+)-布洛芬。34
《手性》:沙利度胺对映体的立体专一性测定、体外手性转化及人体药代动力学。35
沙利度胺对映体与脑蛋白结合蛋白结合的结构基础。36
J-STAGE托管的《化学与药学通报》PDF。37
《美国国家科学院院刊》:稳定型沙利度胺类似物对映体的抗炎与抗肿瘤特性差异。38
布洛芬对映体药代动力学与人体消旋布洛芬剂量之间的关系。39
沙利度胺的立体完整性:用气相色谱测定对映体化障碍。40
沙利度胺分子的死亡与重生。41
《手性》:布洛芬对映体在小鼠、豚鼠和大鼠中的立体选择性药代动力学。42
Soai等人,《自然》,1995年:不对称自催化与手性分子对映体过量的放大。43
播出原貌 21 行
- A chemical reaction produced more than 99.5 percent excess of one mirror-image molecular form. Henri B. Kagan and Kenso Soai have won the 2026 Chemistry Nobel for discoveries that connect that amplification to designing pharmaceutical reactions. How can a tiny molecular preference become overwhelming, and what does that establish about life’s handedness?
- Kagan showed that certain reactions can magnify a preference for one molecular handedness. Soai identified a self-reinforcing reaction in which the product helps make more of itself. Together, those discoveries give chemists ways to favor a desired mirror-image product.
- The confirmed names are Henri B. Kagan and Kenso Soai. Enrique Kagan, Keno Soy and Kenso Soy are mistaken versions, not additional recipients or established alternative names. Their listed university affiliations belong to the award announcement; they do not establish a dated history of appointments.
- The award was announced on October 7, 2026, in Stockholm. Kagan’s listed affiliation is Université Paris-Sud in France, associated with Orsay. Soai’s is Tokyo University of Science in Japan. The recognition spans decades of chemistry, rather than a newly launched medicine.
- The award recognizes non-linear effects and autocatalysis in asymmetric organic synthesis. That means controlling which mirror-image molecular form a reaction favors. It does not declare that the historical origin of biological handedness has been proved.
- Two molecules can share a chemical formula yet differ in their three-dimensional arrangement. When they are mirror images that cannot be superimposed, they are called enantiomers. Biology can distinguish between them, so a medicine’s formula alone does not tell the whole story of its behavior.
- Left and right hands provide the useful analogy: mirror images, but not interchangeable arrangements. Asymmetric synthesis favors one molecular form instead of making both in equal amounts. Homochirality describes the selection or predominance of one handedness.
- Kagan’s work in the 1980s showed that the imbalance in a catalyst and the imbalance in its product need not increase in simple proportion. In suitable reactions, the product can have a stronger preference for one handedness. That is the non-linear effect. It does not mean every asymmetric reaction amplifies handedness. A specific 1986 discovery date and original paper title remain unverified.
- Soai’s published discovery record includes a paper dated December 1, 1995. A July 2002 account described amplification in reactions involving pyrimidine-, quinoline- and pyridine-carbaldehydes. Those publication records do not establish that the later extreme result appeared in the first paper.
- Soai’s feedback mechanism is asymmetric autocatalysis: the chiral product itself helps catalyze production of more of that product. An existing preference can feed back into further production and grow. In the described chemical system, pyrimidyl alkanol acts as the asymmetric autocatalyst in the addition of diisopropylzinc to pyrimidine-5-carbaldehyde.
- The exceptionally small starting imbalance concerns a specific compound, 2-alkynylpyrimidyl alkanol. It is not a result for an unspecified universal reaction. The striking numbers belong to a later research description dated January 22, 2014, rather than quantities established by the available 1995 paper record.
- In that 2-alkynylpyrimidyl alkanol system, approximately 0.00005 percent initial enantiomeric excess was amplified to more than 99.5 percent enantiomeric excess in the same compound. A tiny initial preference became a very strong one through asymmetric autocatalysis.
- Enantiomeric excess measures the imbalance between the two mirror-image forms. It is not chemical yield, and it is not the percentage of all material manufactured. Dividing the final threshold by the nominal starting value gives more than roughly 1.99 million-fold amplification in that measure. Because the starting value is approximate, that ratio is not a separately precise experimental measurement.
- The original experimental date, reaction-cycle count and full procedure remain unidentified. Exact substituents, quantities, solvent, temperature and analytical methods are also missing. Those gaps limit a detailed reconstruction of the experiment; they do not erase the stated amplification result.
- The pharmaceutical consequence is a way to design reactions that favor the intended molecular form. It is not a demonstrated reduction in drug prices, a new treatment, or a guarantee that every manufacturing process becomes safer. The Nobel recognizes discoveries and mechanisms, not those downstream outcomes.
- The chemistry prize totals 12 million Swedish kronor, about 1.2 million dollars. That is the total award, not 12 million kronor for each scientist. An equal split remains unconfirmed, and individual monetary allocations are not independently established.
- Thalidomide shows why familiar drug examples require care. Its disaster belongs to the late 1950s, not the mid-1990s. The asserted figure of 20,000 infant deaths is not verified. Differences between its optical isomers in pharmacological and toxicological activity are described, including an association of the S form with teratogenicity—harm to fetal development.
- That does not establish that the R form is harmless or exclusively therapeutic. Nor does it support a promise that selecting one thalidomide enantiomer eliminates harm. The relevant bodily interconversion results and mechanism remain unestablished in the available evidence.
- The same caution applies to ibuprofen. The claim that tablets contain equal amounts of two mirror-image forms and only one has an effect is not established here. Neither the asserted exclusive activity nor the extent of metabolic conversion between forms can serve as a settled explanation of this Nobel achievement.
- A chemical mechanism can explain how a strong handedness preference can emerge spontaneously. That is different from demonstrating that this particular laboratory reaction occurred before life emerged, or explaining why biology selected a particular handedness. The Soai system examines possibilities; it does not reconstruct life’s origin.
- The discoveries establish how suitable chemical reactions can favor one mirror-image product and amplify a minute initial imbalance into a large one. The actual historical route by which life acquired its molecular handedness remains distinct from what this award establishes.
来源
43 个来源23 家媒体2 个视频2 篇通稿
来源地图
追溯本篇报道的依据。图谱展示其关联;下方链接可打开本文引用的来源。
来源图谱将在您阅读时加载。
译文更新于
修订记录
- r1首次发布。
